Oncopeptides AB
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company's PDC platform desig… Read more
Market Cap & Net Worth: Oncopeptides AB (ONCO)
Oncopeptides AB (ST:ONCO) has a market capitalization of $39.00 Million (Skr437.50 Million) as of March 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #22962 globally and #281 in its home market, demonstrating a 7.36% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Oncopeptides AB's stock price Skr1.69 by its total outstanding shares 258567472 (258.57 Million).
Oncopeptides AB Market Cap History: 2017 to 2026
Oncopeptides AB's market capitalization history from 2017 to 2026. Data shows change from $1.84 Billion to $39.00 Million (-30.01% CAGR).
Oncopeptides AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Oncopeptides AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.13x
Oncopeptides AB's market cap is 1.13 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $3.91 Billion | $19.36 Million | -$1.59 Billion | 202.09x | N/A |
| 2021 | $193.61 Million | $118.30 Million | -$1.43 Billion | 1.64x | N/A |
| 2022 | $280.05 Million | $8.36 Million | -$337.95 Million | 33.52x | N/A |
| 2023 | $176.56 Million | $35.22 Million | -$249.11 Million | 5.01x | N/A |
| 2024 | $35.86 Million | $31.65 Million | -$284.61 Million | 1.13x | N/A |
Competitor Companies of ONCO by Market Capitalization
Companies near Oncopeptides AB in the global market cap rankings as of March 19, 2026.
Key companies related to Oncopeptides AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Oncopeptides AB Historical Marketcap From 2017 to 2026
Between 2017 and today, Oncopeptides AB's market cap moved from $1.84 Billion to $ 39.00 Million, with a yearly change of -30.01%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr39.00 Million | -64.79% |
| 2025 | Skr110.75 Million | +208.80% |
| 2024 | Skr35.86 Million | -79.69% |
| 2023 | Skr176.56 Million | -36.95% |
| 2022 | Skr280.05 Million | +44.64% |
| 2021 | Skr193.61 Million | -95.05% |
| 2020 | Skr3.91 Billion | +33.73% |
| 2019 | Skr2.92 Billion | -3.42% |
| 2018 | Skr3.03 Billion | +64.25% |
| 2017 | Skr1.84 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Oncopeptides AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $39.00 Million USD |
| MoneyControl | $39.00 Million USD |
| MarketWatch | $39.00 Million USD |
| marketcap.company | $39.00 Million USD |
| Reuters | $39.00 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.